Clinical Trial Update: Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC [Phase 2]

View source ↗

Summary

Updates on a Phase 2 trial testing durvalumab plus S-1 as adjuvant therapy for resectable biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Biliary Tract Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING